Technology fund available for UCL innovators to commercialise research

The UCL Technology Fund was created to help UCL achieve the full potential of innovations that have prospects for outstanding global impact and commercial returns. Importantly, profits of the fund are returned to the university over the long term. By doing so the fund continues to support UCL’s mission of pursuing excellence, breaking boundaries and making an impact on real world problems.

Fund 2 has been launched to help bring UCL’s academic research in life, computer and physical sciences to commercial reality, building on its established track record over the last 5 years.

The fund invests both in spinout companies, where a platform technology may have multiple applications, and in small and large-scale academic led projects to accelerate translation. 

Fund 1 supported projects to progress a range of cell and gene therapies, small molecule and biologic products, and semiconductors. It supported spinouts such as:

• Orchard Therapeutics 
• Freeline Therapeutics 
• Phasecraft
• Hazy

Funding available for UCL researchers

UCL researchers with projects which have the potential to make a significant impact on society and generate commercial returns are encouraged to get in touch with UCL Business (UCLB).

There are no specific ‘calls’ for funding. The application process is fast and iterative. 

Explore how the fund can help you by contacting the UCLB Business Manager for your department. You can find your Business Manager on the UCLB website.

The UCL Technology Fund is managed by AlbionVC in collaboration with UCL Business (the university’s commercialisation company and part of UCL Innovation & Enterprise).

Links

Find out more about:

• the launch of Fund 2 (on the UCL News website)
• UCL Technology Fund
• innovation and enterprise support for UCL staff 
• Orchard Therapeutics 
• Freeline Therapeutics 
• Phasecraft
• Hazy